The role of homologous recombination deficiency (HRD), commonly mediated by loss of BRCA1/2 activity, in chemo-responsiveness is not well-defined, and is actively being investigated (NCT01982448). This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.